AGM/EGMJun 12, 2026, 04:17 PM
Vor Biopharma Stockholders Elect Directors, Approve Equity Plan, Ratify Auditor
AI Summary
Vor Biopharma Inc. held its Annual Meeting of Stockholders, where all three proposals were approved. Stockholders elected Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. as Class II Directors to serve until the 2029 Annual Meeting. Additionally, the Amended and Restated 2021 Equity Incentive Plan was approved, and the selection of Ernst & Young LLP as the independent registered public accounting firm for 2026 was ratified.
Key Highlights
- Andrew Levin, M.D., Ph.D. was elected as a Class II Director with 25,797,081 votes For.
- Fouad Namouni, M.D. was elected as a Class II Director with 22,825,938 votes For.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 20,146,430 votes For.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm with 33,877,004 votes For.
- Approximately 62.77% of shares entitled to vote were present or represented at the Annual Meeting.
Price Impact
More from VOR
ESOP4h ago
Vor Bio grants 7 new hires stock options for 71,200 shares & 15,150 RSUs
Business UpdateJun 8, 4:07 PM
Vor Biopharma: Telitacicept approved in China for IgA Nephropathy & Sjögren's Disease
Business UpdateMay 28, 8:32 AM
Vor Bio to Present Corporate Update at Jefferies Global Healthcare Conference